Faeth Therapeutics and Veru posted double-digit stock gains on the same Monday, for reasons that had nothing to do with each other. Faeth used its quarterly numbers to show it is sitting on nine times the cash it had six months ago. Veru used its own earnings call to confirm a trial enrolled faster than…
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Google reCAPTCHA helps protect websites from spam and abuse by verifying user interactions through challenges.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)
You can find more information in our Privacy Policy and Privacy Policy.